Recently, the University of Texas Medical Branch at Galveston collaborated with a Florida company called Clyra Medical Technologies, Inc. to investigate the firm’s proprietary copper iodine antimicrobial and antiviral product called Clyraguard.™ The study team uncovered promising results: the personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by SARS-CoV-2 actually appears to work—it successfully inactivates the COVID-19 virus. This testing was led by Dr. Slobodan Paessler, DVM, PhD.
TrialSite News offers a brief breakdown of this quite promising and fascinating breakthrough. Note, the vendor recently donated what is claimed to be an FDA Class I approved spray to a hospital in Naples, Florida—NCH Healthcare.
What is the Clyraguard product?
Clyraguard is a personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 coronavirus, the cause of COVID-19.
Is the product registered with the U.S. Food and Drug Administration (FDA)?
Yes. It is registered with the FDA as a Class I general purpose disinfectant, according to claims by the company.
What are core features that make it potentially valuable on the market?
Apparently the product features an extremely high antimicrobial efficiency at 99.999% kill rate (complete inactivation), and the recent testing showcases it actually inactivates the COVID-19 coronavirus below the limits of detection of the testing model.
Moreover, it is a clear, colorless and odorless product that has been tested extensively and found to be non-irritating, non-sensitizing, non-toxic and non-staining.
Clyra Medical on their gratitude to Galveston National Lab
Steve Harrison, president of the company, commented, “Dr. Paessler and his team at the Galveston National Lab are experts in this area and the entire organization is highly responsive to help identify solutions in the time of crisis.”
More on Clyra Medical
With a headquarter office in Tampa, Florida, Clyra Medical is an innovative patent-protected copper iodine complex chemistry based on combining compounds that create a gentle but effective oxidative reaction. This reaction is effective against a wide range of organisms that cause disease pathogens. Organisms include viruses, fungi, spores, and antibiotic-resistant strains of bacteria. The company reports the product to be safe, effective, bio-compatible and cost-effective.
Founded in 2012, the company’s leadership evidences a seasoned leadership. The company is subsidiary of BioLargo, a Westminster California-based company. The subsidiary (Clyra) has few employees.
University of Texas Medical Branch & Galveston National Lab: Elite Highly Secure Research
The University of Texas Medical Branch (UTMB) runs the “Galveston National Lab,” a high security National Biocontainment Laboratory housing several Biosafety level 4 research laboratories. Known for its abilities to investigate exotic disease diagnosis and research, GLB is one of the 15 biosecurity level 4 facilities in the United States and the largest one in the world located on an academic campus.
With support from the National Institute of Allergy and Infectious Diseases and National Institutes of Health and with a staff of about 300, University of Texas Medical Branch has been active in COVID-19 related research. They help sponsors develop diagnostics, therapeutics and vaccines to combat the most dangerous diseases in the world. The center just recently they received $3.35 million for COVID-19 research from Sealy & Smith Foundation. In April, University of Texas Medical Branch discovered a possible breakthrough genetic system for combatting COVID-19.
Technology Transfer & Startups out of UTMB
UTMB’s Office of Technology Transfer manages the assets of the university research, including the support and nurturing of spinoff startup ventures. They maintain a staff of professionals to engage with industry.
Dr. Slobodan Paessler, DVM, PhD, Distinguished University Chair in Biodefense at the University of Texas Medical Branch at Galveston
Call to Action: Interested in doing business with UTMB? Contact their business groups. It would appear that Clyra Medical Technologies could be on to a promising product—perhaps investors are interested?